The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been ... It is also facing a class action suit alleging economic injury, as well as a third-party payer class action ...

The settlement arises amidst allegations that Zantac ... Price Action: SNY shares are up 1.02% at $48.45 during the premarket session on the last check Thursday.

Testing last month determined how such dangerous levels of ranitidine ended up in ... Bay assists plaintiffs in all types of class action and mass tort lawsuits, including: Round Up, Hernia ...

The British Columbia Supreme Court has dismissed a proposed class action ... that ranitidine increases the risk for any type of cancer”. Counsel for the plaintiffs in the lawsuits are claiming ...

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer.

GSK admitted no wrongdoing or liability in the settlements, and said they were in the best long-term interest of the company to avoid the risk of continuing litigation. GSK launched Zantac in 1981 ...

That move led to tens of thousands of lawsuits against the drug's manufacturers. The previous year, UK doctors were told to stop prescribing four types of Zantac as a "precautionary measure".

Legal-Bay LLC, a leading pre settlement funding company, reports that November's $2.2 billion ruling against GlaxoSmithKline has still not been distributed to 80,000+ Zantac plaintiffs.